7.65
0.07 (0.99%)
| Penutupan Terdahulu | 7.57 |
| Buka | 7.67 |
| Jumlah Dagangan | 86,938 |
| Purata Dagangan (3B) | 278,975 |
| Modal Pasaran | 160,674,208 |
| Harga / Buku (P/B) | 0.880 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Feb 2022 |
| EPS Cair (TTM) | -3.47 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.08% |
| Nisbah Semasa (MRQ) | 12.60 |
| Aliran Tunai Operasi (OCF TTM) | -100.89 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -59.45 M |
| Pulangan Atas Aset (ROA TTM) | -44.06% |
| Pulangan Atas Ekuiti (ROE TTM) | -57.49% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Cybin Inc. | - | - |
AISkor Stockmoo
| Konsensus Penganalisis | 0.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 0.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -0.50 |
|
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation. It has also developed EMBARK, a psychological support model that integrates clinical approaches to promote supportive healing with psychedelic medicine. The company is headquartered in Toronto, Canada. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 238.24% |
| % Dimiliki oleh Institusi | 41.95% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Deep Track Capital, Lp | 31 Dec 2024 | 1,529,987 |
| Rosalind Advisors, Inc. | 31 Dec 2024 | 810,918 |
| Acorn Capital Advisors, Llc | 31 Dec 2024 | 734,393 |
| Sphera Funds Management Ltd. | 31 Dec 2024 | 538,111 |
| Ikarian Capital, Llc | 31 Dec 2024 | 397,175 |
| Pale Fire Capital Se | 31 Dec 2024 | 60,912 |
| Knott David M Jr | 31 Dec 2024 | 60,446 |
| Advisorshares Investments Llc | 31 Dec 2024 | 50,651 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 10 Feb 2025 | Pengumuman | Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights |
| 15 Jan 2025 | Pengumuman | Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder |
| 13 Jan 2025 | Pengumuman | Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025 |
| 09 Jan 2025 | Pengumuman | Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |